Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
SciScore for 10.1101/2020.05.05.078501: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of this study include sample size, location within a single institutional system, and proprietary manufacturer information, including differences in E gene target sequence. Further studies are required to confirm …
SciScore for 10.1101/2020.05.05.078501: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of this study include sample size, location within a single institutional system, and proprietary manufacturer information, including differences in E gene target sequence. Further studies are required to confirm percent agreement across different platforms and specimen types to expand on our findings. This is of particular importance as there is a lack of standardization of reference materials and quantitfication (copies/vol, TCID50, etc) for LoD determination. Overall, the Cepheid GeneXpert Xpress SARS-CoV-2 assay and the Roche cobas 6800 SARS-CoV-2 assay showed a high level of agreement among patients with high Ct values. This allows for the laboratories to utilize both assays concurrently as fits with local testing algorithms.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
-
